Hims & Hers Health (HIMS) Amortization of Deferred Charges (2020 - 2026)
Hims & Hers Health (HIMS) reported Amortization of Deferred Charges of $5.0 million for Q1 2026, up 225.91% sequentially from -$4.0 million in Q4 2025.
Hims & Hers Health (HIMS) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 7 years of Amortization of Deferred Charges data on file, last reported at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (up 495.56% YoY), and the FY2025 full-year result was $4.5 million, changed N/A from the prior year.
- Amortization of Deferred Charges improved to $5.0 million in Q1 2026, from -$4.0 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $5.0 million in Q1 2026 to a low of -$4.0 million in Q4 2025.
- A 5-year average of $1.1 million and a median of $600000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges changed 0.0% in 2022 and jumped 512.5% in 2025, its largest moves.
- Tracing HIMS's Amortization of Deferred Charges over 5 years: stood at $500000.0 in 2022, then jumped by 40.0% to $700000.0 in 2023, then advanced by 14.29% to $800000.0 in 2024, then plunged by 596.38% to -$4.0 million in 2025, then soared by 225.91% to $5.0 million in 2026.
- Business Quant data shows HIMS's Amortization of Deferred Charges at $5.0 million in Q1 2026, -$4.0 million in Q4 2025, and $4.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.00 Mn |
| Mar 31, 2026 | 5.00 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Sep 30, 2025 | 4.90 Mn |
| Sep 30, 2025 | 4.90 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Dec 31, 2023 | 700,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 600,000.00 |